Transition from unfractionated heparin to low molecular weight heparins
Ghali, W.A.; Pannatier, A.; Tsuyuki, R.T.; Hull, R.D.; MacKay, E.; Quan, H.; Cornuz, J.
Thrombosis and Haemostasis 88(3): 539-540
2002
ISSN/ISBN: 0340-6245 PMID: 12353090 Document Number: 545195
Document emailed within 1 workday
Related Documents
Godoy, I.; Herrera, C.; Zapata, C.; Kunstmann, S.; Abufhele, A.; Corbalán, R. 1998: Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina Revista Medica de Chile 126(3): 259-264Eriksson, E.; Wollter, I.M.; Christenson, B.; Stigendal, L.; Risberg, B. 1988: Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin Thrombosis and Haemostasis 59(2): 284-288
Chigot, P.; De Gennes, C.; Samama, M.M. 1996: Osteoporosis induced either by unfractionated heparin or by low molecular weight heparin Journal des Maladies Vasculaires 21(3): 121-125
Houbouyan, L.L.; Goguel, A.F. 1993: Comparative evaluation of unfractionated and low molecular weight heparins. Results of the French Etalonorme interlaboratory quality control Annales de Biologie Clinique 51(2): 109-117
Osterkorn, D.; Schramm, W.; Szucs, T. 1996: Health care economics evaluation of inpatient treatment of venous thrombosis with unfractionated heparin versus subcutaneous low molecular weight heparin at home Medizinische Klinik 91(9): 607-609
Vermylen, J.G. 1993: Effect of heparin and low molecular weight heparins on platelets Seminars in Thrombosis and Hemostasis 19(Suppl 1): 20-21
Brunkwall, J.; Mätzsch, T.; Bergqvist, D. 1990: The effect of unfractionated and low-molecular-weight heparin on the release of prostacyclin from the arterial wall Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 1(6): 641-645
Iorio, A.; Agnelli, G. 2000: Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis Archives of Internal Medicine 160(15): 2327-2332
Brieger, D.; Dawes, J. 1996: Long-term persistence of biological activity following administration of Enoxaparin sodium (clexane) is due to sequestration of antithrombin-binding low molecular weight fragments--comparison with unfractionated heparin Thrombosis and Haemostasis 75(5): 740-746
Agnelli, G.; Cosmi, B. 1990: Low molecular weight heparins Medicina 10(1): 9-15
Ebell, M.H. 1994: Low molecular weight heparins for DVT Journal of Family Practice 39(5): 501-502
Drouet, L. 1993: Low molecular weight heparins Presse Medicale 22(40): 2002-2008
Fareed, J.; Hoppensteadt, D.; Jeske, W.; Clarizio, R.; Walenga, J.M. 1998: Low molecular weight heparins: are they different? Canadian Journal of Cardiology 14 Suppl E: 28e-34e
Doutremepuich, C.; Puyal, C.; Lalanne, M.C.; Doutremepuich, F.; De Sèze, O. 1990: How to standardize low molecular weight heparins Annales de Biologie Clinique 48(4): 221-225
Samama, M.M.; Michaut-Paterno, F. 1991: Therapeutic indications of low molecular weight heparins Archives des Maladies du Coeur et des Vaisseaux 84(11 Suppl): 1733-1743
Hunt, D. 1998: Low-molecular-weight heparins in clinical practice Southern Medical Journal 91(1): 2-10
Vignes, S.; Meyer, G.; Marjanovic, Z.; Farge-Bancel, D. 1997: Current indications of low-molecular-weight heparins Annales de Medecine Interne 148(2): 154-162
De Lorenzo, F.; Dotsenko, O.; Kakkar, V.V. 2005: Low molecular weight heparins in cardiovascular medicine Minerva Cardioangiologica 53(6): 585-603
Mammen, E.F.; Arcelus, J.; Messmore, H.; Altman, R.; Nurmohamed, M.; Eldor, A. 1999: Clinical differentiation of low molecular weight heparins Seminars in Thrombosis and Hemostasis 25(Suppl 3): 135-144
Horellou, M.H.; Samama, M. 1991: Low molecular weight heparins in everyday practice Journal des Maladies Vasculaires 16(2): 179-183